Britain and America have forged a significant bilateral deal that will preserve zero duties on UK pharmaceutical shipments being sold in the American market.
Agreement Details of the Accord
As part of the deal, the UK has committed to raise spending on medicines through the NHS. This pledge ensures that tariffs on these vital exports will be held at zero for a timeframe of the next three years.
This agreement comes after previous warnings to significantly raise import taxes on patented pharmaceutical products, with figures mentioned up to one hundred percent.
"This agreement with the United Kingdom reinforces the global environment for innovative medicines and brings much-needed equity to U.S.–U.K. pharmaceutical trade," an announcement declared.
Economic Impact
Pharmaceuticals are one of the the United Kingdom's largest goods shipped to the US, which is clearly the primary buyer for leading British pharmaceutical firms.
Statistics indicate that in the 12 months leading up to last September, the UK shipped pharmaceutical products valued at billions to the US. This value accounted for a significant portion of all goods exports in that span.
"This deal safeguards employment, increases funding and sets the stage for the UK to establish itself as a global hub for medical research," the Business and Trade Secretary stated.
Key British Pledges
The pact includes several specific changes from the United Kingdom:
- Price Threshold Increase: The UK will raise the cost ceiling at which it considers new therapies to be prohibitively costly by a quarter.
- Boosted Medicine Funding: There is a goal to increase total NHS spending on medicines from 0.3% of Gross Domestic Product to 0.6% over the following ten-year period.
- Payback Limit: The amount manufacturers must refund to the NHS to prevent overspending will be capped at fifteen percent. Last year, rebates exceeded 20%.
Industry Background
The deal comes amid a long-running tension between the drug companies and the ministers over spending levels and NHS adoption.
The disagreement were heightened by arguments that American patients were paying several times more for the equivalent treatments than people in the UK and Europe.
Over the last 18 months, several large pharmaceutical investments in the UK have been halted or cancelled, while major investments have been directed toward US facilities.
The Science Minister stated that the NHS needed to increase expenditure on treatments, noting that its spending on drugs had declined as a percentage of its total funding over the last ten years.
